Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Expensify Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Expensify Inc trades at $2.3 (market cap $206.99M). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 22.8× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Expensify Inc for 41 Days on average.
| DFTX | EXFY | |
|---|---|---|
Market Cap | $4.71B | $206.99M |
Volume | 1,966,636 | 256,089 |
Sector | Health | Technology |
52-Week High | $48.45 | $2.72 |
52-Week Low | $10.68 | $0.75 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $3.67B | $146.61M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Expensify (EXFY) trades at $2.27, up 1.79% on the day, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 earnings of $0.04 per share, beating estimates, and raised free cash flow guidance. Revenue trends show stabilization around $140M annually, though net income remains negative. Recent news highlights AI-native ERP integrations and European card expansion, signaling growth initiatives.
The outlook is mixed: analyst consensus is bullish with a $13.75 price target, but high P/E of 258.82 and persistent losses pose valuation risks. Investment opportunity lies in execution of AI-driven products and cash flow improvement, while key risks include competitive pressure and failure to achieve sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
